Comparing the Extent to Which Three Different Formulations of LY4100511 (DC-853) Are Made Available in the Body, Alone and in the Presence of a Drug That Reduces Stomach Acid

Inclusion Criteria:

• Body mass index between 18.0 and 32.0 kilograms per meter squared (kg/m2),inclusive, and a body weight of ≥50 kg.

• In good health, as determined by no clinically significant findings from medicalhistory, 12-lead electrocardiogram (ECG) and vital signs measurements, and clinicallaboratory evaluations (congenital nonhemolytic hyperbilirubinemia [e.g., suspicionof Gilbert's syndrome based on total and direct bilirubin] is not acceptable) atscreening and check-in, and from the physical examination at check-in, as assessedby the Investigator (or designee).

Exclusion Criteria:

• Have a 12-lead ECG abnormality that, in the opinion of the Investigator,

• increases the risk associated with participating in the study

• may confound ECG data analysis

• a QTcF: >450 millisecond (msec) for males, or >470 msec for females

• short PR interval <120 msec or PR interval >220 msec

• second or third degree atrioventricular block

• intraventricular conduction delay with QRS >120 msec

• complete right bundle branch block

• left bundle branch block, or

• Wolff Parkinson-White syndrome

• Have a current or recent acute, active infection (for example, for a least 30 daysbefore screening and up to Day -1, participants must have no symptoms or signs ofinfection in the absence of any anti-infective treatment).

• Had any malignancy within the past 5 years. Exceptions: successfully treated basalcell skin carcinoma or squamous cell skin carcinoma, with no evidence of recurrenceor metastatic disease within the 3 years prior to baseline.

• Have inflammatory bowel disease (IBD), including ulcerative colitis or Crohn'sdisease.